Invokana has been a familiar subject in US Food and Drug Administration (FDA) safety releases as of late. In the past year, the FDA issued safety updates on Invokana and diabetic ketoacidosis, serious urinary tract infections, amputation, and kidney failure. The latest warning, which the FDA issued in mid-June 2016, is about Invokana kidney failure.
According to the strengthened warning, the kidneys can suddenly stop functioning in people using Invokana, Invokamet, canagliflozin (generic equivalent), and dapagliflozin. If the kidneys stop functioning, the body is unable to flush waste, resulting in a dangerous accumulation of waste in the body.
The FDA’s strengthened warning came after the regulatory agency received just over 100 adverse event reports relating to Invokana and kidney failure. Adverse event reports are submitted to the FDA to report injuries from a drug or medical device.
In May 2016, the Invokana attorneys at Carey Danis & Lowe covered the FDA’s warning on Invokana amputation. The FDA issued the amputation warning after reviewing data from an ongoing study.
Ask an Invokana attorney at Carey Danis & Lowe about your case. We offer free, no obligation case consultations.
Call 800.721.2519, or complete our confidential online form.References: Invokana